Corporate 18 September 2024 9 mins read

Final results from CABINET Phase III trial reinforce efficacy benefits of Cabometyx® in advanced neuroendocrine tumors

Corporate 16 September 2024 9 mins read

Final results from CABINET Phase III trial reinforce efficacy benefits of Cabometyx® in advanced neuroendocrine tumors

Corporate 15 September 2024 7 mins read

Ipsen provides update on CONTACT-02 Phase III trial in metastatic castration-resistant prostate cancer following final overall survival analysis

Regulated Information 04 September 2024 1 mins read

Ipsen – August 2024 – Monthly information relative to the total number of voting rights and shares composing the share capital

Acquisition/Merger 30 August 2024 1 mins read

Testing video 1

Acquisition/Merger 30 August 2024 1 mins read

Testing video 3

Acquisition/Merger 30 August 2024 1 mins read

Testing video 2

Regulated Information 13 August 2024 1 mins read

IPSEN – Buy-back programme – Art 5 of MAR – Week 32 – 2024

Regulated Information 06 August 2024 1 mins read

IPSEN – Buy-back programme – Art 5 of MAR – Week 31 – 2024

Regulated Information 05 August 2024 1 mins read

Ipsen – July 2024 – Monthly information relative to the total number of voting rights and shares composing the share capital